Part 1: Mechanism of Action
Origins and Development
| Aspect | Description |
|---|
| Original indication | Type 2 diabetes management |
| Primary mechanism | Mimics GLP-1 (glucagon-like peptide-1) hormone |
| Key breakthrough | Semaglutide demonstrated dramatic weight loss beyond glucose control |
| Current status | Marketed under separate brand names for diabetes and obesity |
The Critical Role of Brain Mechanisms
Research has demonstrated that appetite regulation in the brain plays a crucial role in the weight loss observed with these drugs:
- Studies in animal models lacking GLP-1 receptors specifically in the brain showed no weight loss on these medications, despite maintained glucose-lowering effects
- This finding underscores that central appetite suppression is fundamental to efficacy
Two Types of Hunger Affected
| Hunger Type | Description | Drug Effect |
|---|
| Homeostatic | Driven by caloric deficit and depleted energy stores | Satiety signals activated |
| Hedonic | Driven by pleasure/reward from palatable foods | Reward circuits inhibited |
Aversion and Side Effects
Research has identified a distinct population of GLP-1 receptor neurons that drive aversion — these may not contribute to weight loss but are linked to the nausea commonly experienced with these drugs. This understanding opens possibilities for developing refined versions that target appetite centers more precisely while reducing gastrointestinal side effects.
Part 2: Available Medications
Current Brand-Name Options
| Generic Name | Brand (Diabetes) | Brand (Obesity) | Receptor Targets | Relative Potency |
|---|
| Semaglutide | Ozempic | Wegovy | GLP-1 only | Moderate |
| Tirzepatide | Mounjaro | Zepbound | GLP-1 + GIP | High |
| Liraglutide | Victoza | Saxenda | GLP-1 only | Low (not recommended) |
Dosing Comparisons
Semaglutide
- Injectable doses: 0.5 mg, 1 mg, 2 mg, 2.4 mg weekly
- Oral doses: 3 mg, 7 mg, 14 mg daily
- Titration: Gradual increase over 16 weeks minimizes side effects
Tirzepatide
- Injectable doses: 2.5 mg, 5 mg, 10 mg, 15 mg weekly
- 2.5 mg typically used as initiation dose
- Dual mechanism provides greater potency
Semaglutide vs. Tirzepatide
| Factor | Semaglutide | Tirzepatide |
|---|
| Mechanism | GLP-1 agonist only | Dual GLP-1 + GIP agonist |
| Weight loss (trials) | ~17% at max dose | ~22.5% at max dose |
| HbA1c reduction | Similar | Similar |
| Side effect profile | GI symptoms common | GI symptoms common |
| Discontinuation rates | Comparable | Comparable |
| Monthly cost | ~$900–1,300 | ~$1,100 |
Clinical Observation
Patients who plateau on semaglutide and switch to tirzepatide often experience further benefits, likely due to the additional GIP receptor activation.
Oral vs. Injectable Formulations
| Route | Bioavailability | Indication | Efficacy |
|---|
| Injectable | High | Diabetes + Obesity | Maximum weight loss |
| Oral (3, 7, 14 mg) | ~1% (heavy liver metabolism) | Type 2 diabetes (Rybelsus) | Glycemic control |
| Oral (25 mg) | ~1% (higher dose compensates) | Chronic weight management (approved Dec 2025) | ~15% weight loss in trials |
The oral form requires much higher doses due to gastric breakdown and first-pass liver metabolism. A higher-dose 25 mg oral semaglutide formulation for chronic weight management became available as a brand-name obesity medication in early 2026. Novo Nordisk launched it at approximately $149/month.
Part 3: Weight Loss Efficacy
Expected Weight Loss by Medication
| Medication | Trial Duration | Weight Loss | Notes |
|---|
| Semaglutide 2.4 mg (STEP 1)1 | 68 weeks | 14.9% (vs 2.4% placebo) | 69–79% achieved ≥10% loss |
| Tirzepatide 15 mg (SURMOUNT-1)2 | 72 weeks | 22.5% (reduction of 23.6 kg) | 57% achieved ≥20% loss |
| Tirzepatide vs Semaglutide (SURMOUNT-5) | 72 weeks | 20.2% vs 13.7% | Head-to-head; NEJM May 2025 |
| Retatrutide 12 mg | 48 weeks | ~25% | Phase 2 data; Phase 3 (TRIUMPH-4) results announced Dec 2025 |
Long-Term Efficacy
- Four-year data on semaglutide shows weight loss remains stable with continued use
- No evidence of developing resistance to the drug’s effects
- Weight loss appears maintained as long as medication continues
What Happens After Stopping
| Study | Follow-up | Weight Regain |
|---|
| Semaglutide cessation | 52 weeks off drug | ~2/3 of lost weight regained |
| Tirzepatide cessation | 2 years off drug | Most weight regained (within 2–4 kg of baseline) |
Critical Point
For most patients, discontinuing these medications results in substantial weight regain. Exercise appears crucial for weight maintenance post-drug. Research on liraglutide demonstrated that subjects combining exercise with medication lost the most weight and regained weight slowest after stopping.
Factors That May Help Maintain Weight After Stopping
- Gradual tapering rather than abrupt cessation
- Maintained caloric deficit through diet
- Regular exercise (particularly important)
- Lower initial weight loss goals
Part 4: Body Composition Effects
Fat vs. Lean Mass Loss
| Weight Loss Method | Fat Loss | Lean Mass Loss |
|---|
| GLP-1 agonists | ~2/3 of total | ~1/3 of total |
| Dietary restriction | ~2/3 of total | ~1/3 of total |
| Bariatric surgery | ~2/3 of total | ~1/3 of total |
The distribution of fat vs. lean mass loss with GLP-1 agonists is comparable to other weight loss interventions.
Optimizing Body Composition
Tirzepatide study example:
- Starting weight: ~104–105 kg (229–231 lbs)
- Total weight loss: ~24 kg (53 lbs)
- Lean mass loss: 6–7 kg (13–15 lbs)
- Fat mass loss: 17 kg (37 lbs)
- Fat:muscle loss ratio: Nearly 3:1 (highly favorable)
Strategies to Preserve Muscle Mass
| Strategy | Evidence | Implementation |
|---|
| Resistance training | Strong | 2–3 sessions per week minimum |
| Adequate protein | Strong | 1.6–2.2 g/kg body weight daily |
| Gradual weight loss | Moderate | Use lower effective dose |
| DEXA monitoring | Recommended | Track body composition changes |
Key Insight
Patients who focus on resistance training and adequate protein intake tend to achieve more favorable body composition outcomes, losing predominantly fat while preserving muscle.
Part 5: Safety Profile
Overall Safety Assessment
| Finding | Significance |
|---|
| No major life-threatening toxicities identified | Reassuring given widespread use |
| No fen-phen-like catastrophes | Unlike historical weight loss drugs |
| Common side effects are GI-related | Usually manageable with titration |
| Long-term data still accumulating | 4+ years of follow-up available for semaglutide |
Common Side Effects
| Side Effect | Frequency | Management |
|---|
| Nausea | Very common (~50%) | Slow dose titration |
| Diarrhea | Common | Usually transient |
| Constipation | Common (paradoxical) | Fiber, hydration |
| Vomiting | Moderate | Dose adjustment |
Key Insight
About half of patients will experience GI side effects at least temporarily. Slower dose escalation (over 16 weeks as done in trials) significantly reduces side effect burden.
Thyroid Cancer Concerns
| Evidence | Finding |
|---|
| Rat studies | Raised initial concerns |
| Human systematic review (4 years) | Incidence <1% in treated patients |
| Current assessment | No significant signal detected |
| Caveat | Median follow-up only 1–2 years |
Mental Health Considerations
A comprehensive 2024 review found no evidence meeting Bradford Hill criteria for a causal relationship between GLP-1 agonists and depression or suicidal ideation. However, considerations remain:
| Factor | Concern |
|---|
| Rapid weight loss | Can be physiologically stressful |
| Cortisol/norepinephrine spikes | May cause mood disruptions |
| Bariatric surgery parallel | Higher suicide risk observed in surgical patients |
| Individual variability | Some patients may be more susceptible |
Recommendation: Work with an experienced physician who can monitor for psychological side effects and intervene if needed.
Part 6: Broader Health Benefits
The Key Question
Are observed health benefits occurring because of: (1) weight loss and improved metabolic health (indirect effect), or (2) direct, independent effects of the drug itself (pleiotropic effect)? This distinction is crucial for understanding who might benefit from these medications.
Cardiovascular Disease
| Study | Finding | Caveat |
|---|
| SELECT trial4 | 20% reduction in major cardiac events (vs. placebo) | Weight loss difference may confound |
| Heart failure studies | Promising results with semaglutide | Weight loss remains confounding factor |
| Bariatric surgery comparison | 60% reduction in cardiac events | Strongly correlated with weight loss |
Dementia and Neuroprotection
| Evidence Level | Finding |
|---|
| Mechanistic basis | Glucose intolerance/insulin resistance are major Alzheimer’s risk factors |
| Clinical data | 53% reduction in dementia rate vs. placebo (3.8-year follow-up) |
| Comparison to other diabetes drugs | No significant difference when glycemic control matched |
| EVOKE trials (completed 2025) | Phase 3 trials of oral semaglutide in early Alzheimer’s failed to meet primary endpoint; Novo Nordisk discontinued all semaglutide Alzheimer’s trials |
Assessment
Moderate evidence for neuroprotective benefits in metabolic populations, but the EVOKE trial failure (2025) indicates GLP-1 agonists do not slow Alzheimer’s progression. Benefits may be limited to metabolic pathways rather than direct neuroprotection.
Cancer Risk
| Finding | Interpretation |
|---|
| Significant reduction in 10/13 obesity-related cancers | Observed in diabetic patients on GLP-1s vs. insulin |
| Mechanistic basis | Insulin resistance is second leading environmental cancer risk (after smoking) |
| Likely explanation | Reduced hyperinsulinemia rather than direct drug effect |
Kidney Disease
| Study Finding | Context |
|---|
| 24% lower risk of major kidney disease | Semaglutide 1 mg vs. placebo |
| Comparison to SGLT2 inhibitors | No significant difference in renal protection |
| Comparison to Metformin | GLP-1 agonists appear superior |
Fertility in Women
| Mechanism | Effect |
|---|
| Weight loss | Improves fertility in obese women |
| Leptin reduction | May improve reproductive function |
| Delayed gastric emptying | Could affect oral contraceptive absorption |
Substance Use Disorders
| Evidence | Finding |
|---|
| Animal studies | Semaglutide reduces binge-like alcohol consumption |
| Human observational | Reduced nicotine and stimulant use with semaglutide |
| Caveat | May be due to appetite suppression rather than direct effect |
| Status | Promising but needs more research |
Part 7: Emerging Medications and New Developments
Oral Wegovy: Semaglutide Pill for Weight Loss
A higher-dose oral semaglutide formulation (25 mg daily) for chronic weight management became available as a brand-name obesity medication in early 2026. Novo Nordisk launched the product in January 2026.7
| Feature | Oral Wegovy (25 mg) | Injectable Wegovy (2.4 mg) | Rybelsus (3, 7, 14 mg) |
|---|
| Indication | Chronic weight management | Chronic weight management | Type 2 diabetes only |
| Route | Once-daily oral tablet | Once-weekly injection | Once-daily oral tablet |
| Weight loss (trials) | ~15% at 68 weeks | ~17% at 68 weeks | Modest (~3–5%) |
| Absorption enhancer | Yes (SNAC) | Not needed | Yes (SNAC) |
| Fasting requirement | 30 min before food/drink | None | 30 min before food/drink |
| Monthly cost (list) | ~$149/month | >$1,300/month | ~$900–1,000/month |
How Oral Semaglutide Works
The tablet contains sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), an absorption enhancer that protects the semaglutide peptide from stomach acid and facilitates absorption across the gastric lining. Because oral bioavailability is only ~1%, much higher doses (25 mg vs. 2.4 mg injectable) are required to achieve therapeutic levels.
Clinical Trial Data (OASIS 1)
In the pivotal OASIS 1 trial, oral semaglutide 50 mg achieved approximately 15.1% body weight reduction at 68 weeks vs. 2.4% with placebo. The 25 mg dose achieved somewhat less weight loss but with an improved tolerability profile. The side effect profile mirrors injectable semaglutide — predominantly gastrointestinal (nausea, diarrhea, constipation).7
Clinical Significance
Oral Wegovy represents a major step for patients who prefer pills over injections or have needle phobia. However, there are trade-offs: the fasting requirement (must take on an empty stomach with no more than 4 oz of water, then wait 30 minutes before eating or taking other medications) can be inconvenient. The weight loss may be slightly less than injectable Wegovy at maximal doses. Still, for many patients, the convenience of an oral formulation may improve adherence and make GLP-1 therapy accessible to those who would otherwise decline injection-based treatment.
Orforglipron: Eli Lilly’s Oral Small-Molecule GLP-1
Orforglipron (LY-3502970) represents a fundamentally different approach to oral GLP-1 therapy. Unlike oral semaglutide (which is still a peptide requiring an absorption enhancer), orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist — the first of its kind in late-stage development.8
| Feature | Orforglipron | Oral Semaglutide | Injectable GLP-1s |
|---|
| Molecule type | Small molecule (non-peptide) | Peptide | Peptide |
| Absorption enhancer | Not needed | Required (SNAC) | Not applicable |
| Food restrictions | None | Must fast 30 min | None |
| Storage | Room temperature | Room temperature | Refrigeration (until first use) |
| Half-life | 29–49 hours | ~7 days (once absorbed) | Varies by agent |
| Dosing | Once daily | Once daily | Once weekly |
| Manufacturing | Standard chemical synthesis | Complex peptide synthesis | Complex peptide synthesis |
Phase 3 ACHIEVE-1 Trial Results (April 2025)
| Outcome | Orforglipron (highest dose) | Placebo |
|---|
| HbA1c reduction | 1.3–1.6 percentage points | Modest |
| Participants reaching non-diabetic HbA1c | >65% | — |
| Weight loss at 40 weeks | ~8% (~16 lbs / 7.3 kg) | — |
| Weight loss plateau reached? | No (still declining at study end) | — |
The ACHIEVE-1 trial enrolled 559 people with type 2 diabetes. More than 65% of participants on the highest dose achieved HbA1c reductions into the non-diabetic range. Participants also lost approximately 8% of body weight (~16 lbs) at 40 weeks, and importantly, weight loss had not plateaued at study’s end, suggesting greater reductions with longer treatment.8
Side effects: Similar to injectable GLP-1 agonists — gastrointestinal symptoms (nausea, diarrhea, constipation) were most common, affecting 44–70% of orforglipron-treated participants (vs. 18% placebo), mostly mild to moderate severity. No significant liver safety signals were detected.
Why Orforglipron Matters
- No food restrictions: Unlike oral semaglutide, patients can take it with food
- Room temperature storage: No refrigeration needed, simplifying storage and shipping
- Cheaper to manufacture: Small molecules are produced via standard chemical synthesis, not complex peptide manufacturing — this could dramatically reduce costs
- Scalable production: Easier to manufacture at large scale, potentially addressing the supply shortages that have plagued injectable GLP-1s
- No absorption enhancer needed: The small-molecule structure is inherently orally bioavailable
Timeline: Phase 3 obesity-specific trials (ACHIEVE program) are ongoing. Eli Lilly is expected to file for FDA approval for both type 2 diabetes and obesity indications. Market availability is projected for 2026–2027.
Retatrutide: The Triple Agonist
Retatrutide is Eli Lilly’s triple-hormone receptor agonist — the first drug to simultaneously activate GLP-1, GIP, and glucagon receptors. This “triple agonist” approach goes beyond the dual agonism of tirzepatide by adding glucagon receptor activation, which independently increases energy expenditure and promotes fat oxidation.3
| Feature | Description |
|---|
| Mechanism | GLP-1 + GIP + Glucagon receptor agonist (triple agonist) |
| Status | Phase 3 completed (TRIUMPH program); FDA approval projected ~2027 |
| Weight loss | ~25% at highest dose (48 weeks, Phase 2); Phase 3 confirms robust efficacy |
| Comparison | More potent than both semaglutide and tirzepatide |
Why Triple Agonism Matters
| Receptor | Role in Weight Loss | Unique Contribution |
|---|
| GLP-1 | Appetite suppression, insulin secretion | The foundation — proven mechanism from semaglutide |
| GIP | Enhances GLP-1 effects, fat metabolism | Amplifies weight loss — the “dual agonist” advantage from tirzepatide |
| Glucagon | Increases energy expenditure, promotes hepatic fat oxidation, thermogenesis | New addition — burns more calories at rest, reduces liver fat |
The glucagon receptor activation is what distinguishes retatrutide from tirzepatide. While glucagon traditionally raises blood sugar (which would be counterproductive), the simultaneous GLP-1 and GIP activation counterbalances this effect, allowing the metabolic benefits of glucagon (increased energy expenditure, fat burning) without problematic hyperglycemia.
Phase 2 Trial Results (NEJM, 2023)3
| Dose | Weight Loss at 48 Weeks |
|---|
| 1 mg | 8.7% |
| 4 mg (with ramp-up) | ~15% |
| 8 mg (with ramp-up) | ~20% |
| 12 mg (with ramp-up) | ~25% |
Phase 3 TRIUMPH Program Results (December 2025)
Eli Lilly announced positive results from the TRIUMPH Phase 3 program. The TRIUMPH-3 and TRIUMPH-4 trials confirmed retatrutide’s robust weight loss efficacy in adults with obesity, with results consistent with the impressive Phase 2 data. Full data from the TRIUMPH trials are expected to be published in peer-reviewed journals and presented at major medical conferences in 2026.
Receptor Activity Profile
| Receptor | Retatrutide | Semaglutide | Tirzepatide |
|---|
| GLP-1 | 0.4 | 0.5 | 0.2 |
| GIP | 8.9 | None | Present |
| Glucagon | 0.3 | None | None |
Key Insight
The exceptional GIP activity appears to be the primary driver of retatrutide’s superior weight loss, more so than the glucagon component. However, the glucagon receptor activation likely contributes to additional metabolic benefits, particularly liver fat reduction and increased energy expenditure.3 Safety profile is similar to other GLP-1 agonists. If approved (~2027), retatrutide would become the most potent anti-obesity medication available, potentially achieving weight loss approaching that of bariatric surgery.
Part 8: Practical Considerations
Cost and Accessibility
| Medication | Monthly Cost | Annual Cost |
|---|
| Wegovy (semaglutide) | >$1,300 | ~$16,000 |
| Ozempic (semaglutide) | $900–1,200 | ~$11,000–14,000 |
| Zepbound (tirzepatide) | ~$1,100 | ~$13,000 |
Discontinuation data: 25–35% of patients discontinue primarily due to cost, not side effects.
Note on insurance and Highland's practice: The brand-name pricing above reflects retail cost for brand-name products that Highland Longevity does not dispense. Insurance coverage, when available, typically applies only to brand-name products — not to the compounded semaglutide and compounded tirzepatide that Highland prescribes. Compounded medications are generally not covered by health insurance.
Compounding Pharmacies
Compounded versions exist due to cost savings and periodic drug shortages. However, safety concerns are significant when sourcing from unverified vendors:
| Risk | Finding |
|---|
| Illegal vendors | 42% of online semaglutide sellers operating illegally |
| Contamination | Some vials contained endotoxins |
| Purity issues | Concentrations ranged from 10% to 139% of advertised |
Checklist for Choosing a Compounding Pharmacy
- Verify no complaints on state licensing board website
- Request latest state board inspection report
- Confirm PCAB accreditation
- Request certificate of analysis
- Confirm semaglutide is base form (not salt form)
- Verify third-party testing for potency and sterility
Highland Longevity's medical weight loss approach: Highland prescribes compounded semaglutide and compounded tirzepatide only, sourced through a state-licensed compounding pharmacy under our physician's supervision. Compounded medications are not FDA-approved — your physician will discuss the implications, risks, and benefits at your consultation.
Eli Lilly’s Vial Option
Eli Lilly is releasing tirzepatide vials at reduced cost: 28-day supply of 2.5 mg at $399 (vs. ~$1,200 for pen), eliminating the need for single-use injector pens.
Part 9: Remaining Questions
| Question | Current Status |
|---|
| Cyclic use effects | Anecdotal reports of reduced efficacy with on-off cycling |
| Rebound appetite | Some patients report intense hunger after stopping |
| Adolescent effects | Concerns about bone mineral density during puberty |
| Long-term safety | Still accumulating data beyond 4 years |
| Individual risk factors | Cannot yet predict who may have adverse reactions |
Recommendations Against Cycling
- Avoid using high doses for rapid weight loss then stopping
- Lower doses with slower weight loss may be more sustainable
- If stopping, ensure exercise and diet can maintain results
- Ideally, plan for long-term use if medication proves helpful
Key Takeaways
Who May Benefit
| Candidate | Rationale |
|---|
| BMI ≥30 | Primary obesity indication |
| BMI ≥27 with comorbidity | Weight-related health conditions |
| Type 2 diabetes | Original indication, proven efficacy |
| Failed lifestyle interventions | When diet/exercise insufficient |
| High cardiovascular risk | Potential cardioprotective benefits |
Critical Success Factors
- Combine with lifestyle changes: Resistance training and adequate protein are essential
- Plan for long-term use: Most patients regain weight after stopping
- Work with a physician: Essential for safety monitoring and dose optimization
- Focus on body composition: Not just weight loss
- Monitor psychological effects: Be aware of mood changes
Hierarchy of Current Medications
| Rank | Medication | Notes |
|---|
| 1 | Retatrutide | Most potent (if approved) |
| 2 | Tirzepatide | Currently most effective available |
| 3 | Semaglutide | Effective, longest track record |
| 4 | Liraglutide | Not recommended for weight loss |
Key Studies & Data Summary
| Finding | Result | Significance |
|---|
| STEP 1 (semaglutide 2.4 mg)1 | 14.9% weight loss vs 2.4% placebo at 68 weeks | First large-scale obesity trial |
| SURMOUNT-1 (tirzepatide 15 mg)2 | 22.5% weight loss at 72 weeks | First drug to achieve >20% mean weight loss |
| SELECT trial (semaglutide)4 | 20% reduction in major cardiac events | FDA approval for CV risk reduction |
| Weight regain after cessation | 2/3 of lost weight regained within 1 year | Supports need for long-term therapy |
| Body composition | Fat:lean loss ratio ~2:1 | Comparable to other weight loss methods |
| STEP UP (semaglutide 7.2 mg) | 20.7% weight loss at 72 weeks | Higher dose under investigation |
Additional Considerations
Study Limitations
- Trial populations: STEP and SURMOUNT enrolled predominantly female, White participants; generalizability to other populations uncertain
- Follow-up duration: Most trials are 68–72 weeks; very long-term (>5 year) data limited
- Weight maintenance studies: Few trials designed to study post-cessation outcomes
- Body composition assessment: Not all trials included DEXA or detailed body composition analysis
Conflicting Evidence
- Muscle loss concerns: Initial reports suggested up to 50% lean mass loss; more rigorous data shows ~33%, comparable to other weight loss methods
- Cardiovascular effects: GLP-1 agonists raise heart rate by 3–4 bpm, but cardiovascular outcomes are favorable4
- Mental health: European regulators investigated suicidal ideation reports, but comprehensive reviews found no causal link
Individual Variation
- Weight loss response: Not all patients achieve trial-level weight loss; 10–15% may be “non-responders”
- Side effect tolerance: GI symptoms range from mild/transient to requiring discontinuation
- Optimal dose: Some patients plateau at lower doses; dose escalation may be needed
- Switching agents: Patients who plateau on semaglutide may benefit from switching to tirzepatide
Safety Notes
- GI side effects: Nausea occurs in ~50% of patients; slow titration over 16+ weeks reduces severity1
- Pancreatitis: Rare but reported; monitor for severe abdominal pain
- Thyroid cancer: Black box warning based on rodent data; no clear signal in human studies through 4 years
- Gallbladder disease: Increased risk of cholelithiasis with rapid weight loss
- Pregnancy: Discontinue at least 2 months before planned conception (semaglutide) due to long half-life
Recent Developments
- SURMOUNT-5 (NEJM, May 2025): Head-to-head trial: tirzepatide achieved 20.2% weight loss vs semaglutide 13.7% at 72 weeks
- Retatrutide TRIUMPH-4 (Dec 2025): Phase 3 results announced by Eli Lilly; FDA approval projected ~2027
- Oral semaglutide for obesity: 25 mg oral semaglutide became available as a brand-name weight-management medication in early 2026; launched at ~$149/month
- EVOKE trials (2025): Semaglutide failed to slow Alzheimer’s progression in Phase 3 EVOKE trials; Novo Nordisk discontinued Alzheimer’s program
- CV indication (2024): Wegovy approved for cardiovascular risk reduction in adults with obesity and heart disease4
- Survodutide: Glucagon/GLP-1 dual agonist achieved ~18–19% weight loss in Phase 2 trials; SYNCHRONIZE Phase 3 trials are ongoing
- ADA 2026 Standards of Care: Expanded GLP-1 RA indications to include MASH, HFpEF, type 1 diabetes with obesity, and CKD
References
- Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. doi:10.1056/NEJMoa2206038
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. doi:10.1056/NEJMoa2301972
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 389(24), 2221–2232. doi:10.1056/NEJMoa2307563
- Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA, 325(14), 1414–1425. doi:10.1001/jama.2021.3224
- Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet, 402(10402), 613–626. doi:10.1016/S0140-6736(23)01200-X
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of February 2026 and may be updated as new evidence becomes available.